Genetic Technologies Limited (GENE)
Company Description
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons.
In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes.
Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom.
Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Country | Australia |
Founded | 1989 |
Industry | Diagnostics & Research |
Sector | Healthcare |
Employees | 60 |
CEO | Simon Morriss |
Contact Details
Address: 60-66 Hanover Street Fitzroy, Victoria, C3 3065 Australia | |
Phone | 011613-9415-1135 |
Website | gtglabs.com |
Stock Details
Ticker Symbol | GENE |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001166272 |
CUSIP Number | 37185R208 |
ISIN Number | US37185R4065 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Simon Morriss | Chief Executive Officer |
Tony Di Pietro AGIA, B.Com, C.A., CPA, M.A.I.C.D. | Chief Financial Officer and Company Secretary |
Carl S. Stubbings BSc | Chief Commercial Officer |
Kevin Camilleri | Chief Executive Officer of EasyDNA |
Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA | Consultant |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2024 | 6-K | Report of foreign issuer |
Mar 25, 2024 | 6-K | Report of foreign issuer |
Mar 22, 2024 | 6-K | Report of foreign issuer |
Mar 21, 2024 | 6-K | Report of foreign issuer |
Mar 7, 2024 | 6-K | Report of foreign issuer |
Feb 26, 2024 | 6-K | Report of foreign issuer |
Feb 20, 2024 | 6-K | Report of foreign issuer |
Feb 15, 2024 | 6-K | Report of foreign issuer |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 7, 2024 | 6-K | Report of foreign issuer |